Day One Biopharmaceuticals Reports $30.8M Revenue in Q1 2025, Significant Loss Reduction

Day One Biopharmaceuticals, Inc. reported its financial results for the first quarter of 2025, revealing a total revenue of $30.8 million, a significant increase from zero revenue in the same period last year. This revenue was primarily driven by product sales of OJEMDA, which generated $30.5 million, alongside $258,000 in license revenue. The company’s net loss for the quarter was $36.0 million, a notable improvement compared to a net loss of $62.4 million in the first quarter of 2024, reflecting a 42.3% reduction in losses.

The company’s operating expenses rose to $71.8 million, up from $66.8 million in the prior year, largely due to increased selling, general, and administrative expenses, which grew by 10.4% to $29.3 million. Research and development expenses slightly decreased to $39.6 million from $40.2 million, attributed to a reduction in personnel-related costs despite an increase in clinical trial activities. The company’s cash and cash equivalents, along with short-term investments, totaled $473.0 million as of March 31, 2025, down from $125.0 million at the end of 2024, primarily due to cash used in operating activities.

In terms of strategic developments, Day One Biopharmaceuticals has made significant strides in its product pipeline. The FDA approved OJEMDA in April 2024 for treating patients with relapsed or refractory pediatric low-grade glioma (pLGG), marking a pivotal moment for the company. The approval has allowed the company to commence commercial sales, and it has also entered into a licensing agreement with Ipsen for the commercialization of tovorafenib outside the United States, which includes an upfront payment of $70.8 million and potential future milestone payments.

Operationally, the company has seen a substantial increase in customer engagement, with two customers accounting for 98.4% of total net product revenue for the quarter. The company is also expanding its clinical trials, with ongoing studies for tovorafenib in multiple regions, including the U.S., Canada, Europe, Australia, and Asia. As of March 31, 2025, the company employed a total of 200 staff members, reflecting its growth and commitment to advancing its research and development efforts.

Looking ahead, Day One Biopharmaceuticals anticipates continued investment in its product development pipeline, particularly in expanding the clinical trials for OJEMDA and other candidates. The company expects to utilize its cash reserves to support these initiatives and is exploring additional financing options to ensure sufficient capital for its operational needs. The management remains optimistic about the potential for future revenue growth as it continues to advance its innovative therapies for pediatric and adult diseases.